Cutaneous injection site reactions to long-term therapy with enfuvirtide

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 4, 2004, Pages 678-681

  Maggi, Paolo ^a   Ladisa, Nicoletta ^a   Cinori, Eliana ^a   Altobella, Andrea ^b   Pastore, Giuseppe ^a   Filotico, Raffaele ^b  

^a UNIVERSITY OF BARI   (Italy)

^b POLICLINICO   (Italy)

Author keywords

Antiretroviral therapy; HIV 1 fusion inhibitors; Peptide inhibitors

Indexed keywords

ANTIBODY; CD20 ANTIBODY; CD34 ANTIGEN; CD45 ANTIGEN; ENFUVIRTIDE; EOSIN; HEMATOXYLIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADIPOSE TISSUE; ADNEXA DISEASE; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONNECTIVE TISSUE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; INJECTION SITE; LONG TERM CARE; PERIODIC ACID SCHIFF STAIN; PREVALENCE; PUNCH BIOPSY; REMISSION; SCLERODERMA; SKIN BIOPSY; SKIN DEFECT; SKIN INFILTRATE; SKIN MANIFESTATION; STAINING; T LYMPHOCYTE; TISSUE REGENERATION; URTICARIA; VASCULITIS;

ADMINISTRATION, CUTANEOUS; ADULT; FEMALE; HIV ENVELOPE PROTEIN GP41; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; SKIN; TIME FACTORS; URTICARIA;

EID: 3543087801     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh141     Document Type: Article

References (8)

1. Delfraissy, J. F., Montaner, J., Eron, J. et al. for the TORO Study Team. (2003). Summary of pooled efficacy and safety analyses of enfuvirtide (ENF) treatment for 24 weeks in TORO 1 and TORO 2 phase III trials in highly antiretroviral (ARV) treatment-experienced patients. In Program and Abstracts of the Tenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2003. Abstract 568, p. 260. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
2. Lalezari, J. P., Eron, J. J., Carlson, M. et al. (2003). A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 17, 691-8.
3. Chen, R. Y., Kilby, J. M. & Saag, M. S. (2002). Enfuvirtide. Expert Opinion on Investigational Drugs 1, 1837-43.
4. Kilby, J. M., Lalezari, J. P., Eron, J. J. et al. (2002). The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Research and Human Retroviruses 18, 685-93.
5. Lazzarin, A., Clotet, B., Cooper, D. et al. (2003). Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. New England Journal of Medicine 348, 2186-95.
6. Lalezari, J. P., Henry, K., O'Hearn, M. et al. (2003). Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. New England Journal of Medicine 348, 2175-85.
7. Ball, R. & Kinchelow, T. for the ISR Substudy Group. (2003). Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. Journal of the American Academy of Dermatology 49, 826-31.
8. Lalezari, J. P., Patel, I. H., Zhang, X. et al. (2003). Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. Journal of Clinical Virology 28, 217-22.